Rheumatology

AbbVie, Allergan Merger Puts IL-23 Inhibitor Competition in Doubt

May 7th 2020

By Tony Hagen

The Federal Trade Commission was deeply divided over whether the AbbVie-Allergan $63 billion merger plan would allow for a sufficiently competitive marketplace.

Gedeon Richter Buys Mycenax's Tocilizumab Biosimilar

May 5th 2020

By Skylar Jeremias

Article

Interest in tocilizumab has grown lately as Roche has a clinical trial underway to evaluate efficacy in coronavirus disease 2019 (COVID-19)–related pneumonia.

Teva, Celltrion Maintain Slender Discount to Rituxan

May 4th 2020

By Tony Hagen

Article

Although Pfizer has offered a more attractive discount for its rituximab biosimilar, Teva Pharmaceutical Industries and Celltrion Healthcare have decided not to match that discount for their own rituximab biosimilar, which is more costly.

New Zealand Study Reveals Importance of Patient Attitudes Toward Biosimilars

April 24th 2020

By Tony Hagen

Article

A New Zealand study of patients with rheumatic conditions suggests that providers need to be mindful of patient attitudes toward biosimilars to prevent biased therapy choices and poor outcomes.

AMCP Posters Demonstrate Value of Biosimilars

April 20th 2020

By Skylar Jeremias

Article

Posters presented at the Academy of Managed Care Pharmacy (AMCP) eLearning Days meeting this week from April 20 to 24 reveal important data on biosimilar utilization management, switching, and affordability.

American Rheumatology Network Promotes a Biosimilar Pathway

April 19th 2020

By Skylar Jeremias

Article

A pathway model that incorporated use of biosimilars has shown great promise, according to Colin C. Edgerton, MD, executive chairman of the American Rheumatology Network.

Patient Awareness of Biosimilars Is Poor in Australia, Study Says

April 17th 2020

By Deana Ferreri, PhD

Article

Patients in an Australian clinic were generally open to using biosimilars but knew little about them, according to a recent study.

AbbVie Patents Are Costly for Healthcare Consumers

April 11th 2020

By Tony Hagen

Article

The Danish medical system saved 82.8% on adalimumab by switching almost all patients from the reference product to biosimilars, but such a benefit for the US healthcare system may not be possible, according to a new study.

Pfizer Gains European Commission Approval for Rituximab Biosimilar

April 2nd 2020

By The Center for Biosimilars

Article

Following close on the heels of its US approval for Ruxience (rituximab), Pfizer has gained the European Commission nod and aims to launch in coming months.

Study: Employers Can Save With Biosimilars

April 1st 2020

By Skylar Jeremias

Article

Self-insured companies could have saved $407 million to $1.4 billion in 2018 had they switched completely from reference biologics infliximab and filgrastim to biosimilars.